A new study reports one of the biggest potential advances against heart failure in more than a decade — a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20 per cent. Doctors say the Novartis drug — which doesn't have a name yet — seems like one of those rare, breakthrough therapies that could quickly change care for more than half of the 6 million Americans and 24 million people worldwide with heart failure. "This is a new day" for patients, said Dr. Clyde Yancy, cardiology chief at Northwestern University in Chicago and a former American Heart Association president. It involved nearly 8,500 people in 47 countries and was the largest experiment ever done in heart failure.
Read More http://ift.tt/1ptk7pc
No comments:
Post a Comment